Literature DB >> 26201404

New dry powders for inhalation containing temozolomide-based nanomicelles for improved lung cancer therapy.

Rémi Rosière1, Michel Gelbcke2, Véronique Mathieu3, Pierre Van Antwerpen2, Karim Amighi1, Nathalie Wauthoz1.   

Abstract

Besides the numerous advantages of a chemotherapy administered by the inhalation route for lung cancer therapy, dry powder for inhalation (DPI) offers many advantages compared to other techniques and seems to be a technique that is well-adapted to an anticancer treatment. DPI formulations were developed using the cytotoxic drug temozolomide and a new folate-grafted self-assembling copolymer, a conjugate of three components, folate-polyethylene glycol-hydrophobically-modified dextran (F-PEG-HMD). F-PEG-HMD was synthesized using carbodiimide-mediated coupling chemistry in three main steps. F-PEG-HMD was characterized by 1H-NMR, mass spectrometry and thermal analysis. F-PEG-HMD presented a critical micellar concentration in water of 4x10-7 M. F-PEG-HMD nanomicelles were characterized by a trimodal particle size distribution with Z-average diameter of 83±1 nm in water. Temozolomide-loaded nanomicelles were prepared by solubilization of F-PEG-HMD in the presence of temozolomide. Temozolomide solubility in water was increased in the presence of F-PEG-HMD (2-fold increase in molar solubility) which could potentially lead to increased local concentrations in the tumor site. The temozolomide-loaded F-PEG-HMD nanomicelles were characterized by a Z-average diameter of ~50 to ~60 nm, depending on the F-PEG-HMD concentration used. The nanomicelles were then spray-dried to produce dry powders. Temozolomide remained stable during all the formulation steps, confirmed by similar in vitro anticancer properties for the DPI formulations and a raw temozolomide solution. Two of the developed DPI formulations were characterized by good aerodynamic properties (with a fine particle fraction of up to 50%) and were able to release the F-PEG-HMD nanomicelles quickly in aqueous media. Moreover, in vitro, the two DPI formulations showed wide pulmonary deposition in the lower respiratory tract where adenocarcinomas are more often found. The present study, therefore, shows that F-PEG-HMD-based dry powders for inhalation could constitute an interesting drug delivery system able to release nanomicelles that are useful in adenocarcinomas that overexpress folate receptors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26201404     DOI: 10.3892/ijo.2015.3092

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  4 in total

Review 1.  Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.

Authors:  Sharad Mangal; Wei Gao; Tonglei Li; Qi Tony Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

2.  Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy.

Authors:  Jyothi U Menon; Aneetta Kuriakose; Roshni Iyer; Elizabeth Hernandez; Leah Gandee; Shanrong Zhang; Masaya Takahashi; Zhang Zhang; Debabrata Saha; Kytai T Nguyen
Journal:  Sci Rep       Date:  2017-10-16       Impact factor: 4.379

3.  Thermodynamic Solubility Profile of Temozolomide in Different Commonly Used Pharmaceutical Solvents.

Authors:  Abdul Ahad; Faiyaz Shakeel; Mohammad Raish; Ajaz Ahmad; Yousef A Bin Jardan; Fahad I Al-Jenoobi; Abdullah M Al-Mohizea
Journal:  Molecules       Date:  2022-02-21       Impact factor: 4.411

Review 4.  Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies.

Authors:  Malak Abedalthagafi
Journal:  Oncotarget       Date:  2018-10-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.